000141612 000__ 01586fam\a2200361\a\4500
000141612 001__ 141612
000141612 005__ 20220217103226.0
000141612 008__ 920310s1992\\\\dcua\\\\\b\\\f000\0\eng\d
000141612 020__ $$a0160375010
000141612 035__ $$a(OCoLC)ocm25422136
000141612 035__ $$9(IS)TVR5259
000141612 035__ $$9AAQ7037SI
000141612 035__ $$a141612
000141612 040__ $$dGPO
000141612 043__ $$an-us---
000141612 049__ $$aISUW
000141612 074__ $$a1019-A
000141612 0860_ $$aY 4.En 2/3:102-77
000141612 088__ $$aSerial no. 102-77 (United States. Congress. House. Committee on Energy and Commerce)
000141612 090__ $$aRS55.2$$b.U5H8 1991b
000141612 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Energy and Commerce.$$bSubcommittee on Oversight and Investigations.
000141612 24510 $$aFDA's generic drug enforcement and approval process :$$bhearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991.
000141612 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1992.
000141612 300__ $$aiii, 587 p. :$$bill. ;$$c24 cm.
000141612 500__ $$aDistributed to some depository libraries in microfiche.
000141612 500__ $$aShipping list no.: 92-185-P.
000141612 500__ $$a"Serial no. 102-77."
000141612 504__ $$aIncludes bibliographical references.
000141612 61010 $$aUnited States.$$bFood and Drug Administration.
000141612 650_0 $$aPharmaceutical industry$$zUnited States$$xCorrupt practices.
000141612 650_0 $$aPharmaceutical industry$$zUnited States$$xQuality control.
000141612 650_0 $$aGeneric drugs$$zUnited States.
000141612 85230 $$bdfich$$hY 4.EN 2/3:$$i102-77
000141612 909CO $$ooai:library.usi.edu:141612$$pGLOBAL_SET
000141612 948__ $$ac:mgf
000141612 980__ $$aBIB
000141612 980__ $$aGOV RESOURCE